Sanofi Plunges 5.44% on Mixed COPD Trial Results

On May 30, 2025, Sanofi's stock experienced a significant drop of 5.44% in pre-market trading.

Sanofi and Regeneron announced mixed results from their Phase III trials evaluating the IL-33 antagonist itepekimab for COPD patients. The AERIFY-1 trial met its primary endpoint, showing a 27% reduction in the annual rate of moderate or severe exacerbations compared to placebo. However, the AERIFY-2 trial did not achieve the same primary endpoint, despite early indications of benefit.

JPMorgan maintained its 'Neutral' rating on Sanofi, setting a price target of 110 euros. This decision comes amidst the mixed trial results, which have raised questions about the efficacy of itepekimab in treating COPD.